Updated Jul 16, 2026
Booth Bruce has filed 7 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $110.38M.

Bruce Booth is a prominent figure in the biopharmaceutical industry, known for his leadership roles in companies focused on innovative treatments for genetic diseases. He has been involved with Sionna Therapeutics and Vigil Neuroscience, contributing to advancements in therapies for cystic fibrosis and neurological conditions.
| Role | Insider |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 130 | $111.20 | $14K |
| 2026-07-02 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 1.1K | $110.67 | $119K |
| 2026-07-02 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 1.1K | $109.75 | $121K |
| 2026-07-02 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 1.5K | $108.28 | $162K |
| 2026-07-02 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 2.7K | $107.76 | $291K |
| 2026-07-02 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 2.1K | $106.63 | $227K |
| 2026-07-02 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 770 | $105.78 | $81K |
| 2026-07-02 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 934 | $111.20 | $104K |
| 2026-07-02 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 7.7K | $110.67 | $855K |
| 2026-07-02 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 8.0K | $109.75 | $874K |
| 2026-07-02 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 10.8K | $108.28 | $1.17M |
| 2026-07-02 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 19.4K | $107.76 | $2.09M |
| 2026-07-02 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 14.8K | $106.63 | $1.58M |
| 2026-07-02 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 5.5K | $105.78 | $587K |
| 2026-06-30 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 157 | $111.20 | $17K |
| 2026-06-30 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 1.2K | $110.67 | $133K |
| 2026-06-30 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 1.2K | $109.75 | $136K |
| 2026-06-30 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 1.7K | $108.28 | $183K |
| 2026-06-30 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 907 | $111.20 | $101K |
| 2026-06-30 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 7.6K | $110.67 | $841K |
Bruce Booth is a prominent figure in the biopharmaceutical industry, known for his leadership roles in companies focused on innovative treatments for genetic diseases. He has been involved with Sionna Therapeutics and Vigil Neuroscience, contributing to advancements in therapies for cystic fibrosis and neurological conditions.…
7 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 104 open-market sales ($110.38M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Booth Bruce profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.